<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-title>Journal of Neuroinflammation</journal-title><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15642121</article-id><article-id pub-id-type="pmc">PMC545941</article-id><article-id pub-id-type="publisher-id">1742-2094-2-1</article-id><article-id pub-id-type="doi">10.1186/1742-2094-2-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Differential regulation of A&#x003b2;42-induced neuronal C1q synthesis and microglial activation</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Fan</surname><given-names>Rong</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>rfan@uci.edu</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Tenner</surname><given-names>Andrea J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>atenner@uci.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Molecular Biology and Biochemistry, Institute of Brain Aging and Dementia, University of California, Irvine, Irvine, CA 92697 USA</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>10</day><month>1</month><year>2005</year></pub-date><volume>2</volume><fpage>1</fpage><lpage>1</lpage><ext-link ext-link-type="uri" xlink:href="http://www.jneuroinflammation.com/content/2/1/1"/><history><date date-type="received"><day>18</day><month>11</month><year>2004</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Fan and Tenner; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Fan and Tenner; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Fan
               Rong
               
               rfan@uci.edu
            </dc:author><dc:title>
            Differential regulation of A&#x003b2;42-induced neuronal C1q synthesis and microglial activation
         </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>Journal of Neuroinflammation 2(1): 1-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1742-2094(2005)2:1&#x0003c;1&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1742-2094</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Expression of C1q, an early component of the classical complement pathway, has been shown to be induced in neurons in hippocampal slices, following accumulation of exogenous A&#x003b2;42. Microglial activation was also detected by surface marker expression and cytokine production. To determine whether C1q induction was correlated with intraneuronal A&#x003b2; and/or microglial activation, D-(-)-2-amino-5-phosphonovaleric acid (APV, an NMDA receptor antagonist) and glycine-arginine-glycine-aspartic acid-serine-proline peptide (RGD, an integrin receptor antagonist), which blocks and enhances A&#x003b2;42 uptake, respectively, were assessed for their effect on neuronal C1q synthesis and microglial activation. APV inhibited, and RGD enhanced, microglial activation and neuronal C1q expression. However, addition of A&#x003b2;10&#x02013;20 to slice cultures significantly reduced A&#x003b2;42 uptake and microglial activation, but did not alter the A&#x003b2;42-induced neuronal C1q expression. Furthermore, A&#x003b2;10&#x02013;20 alone triggered C1q production in neurons, demonstrating that neither neuronal A&#x003b2;42 accumulation, nor microglial activation is required for neuronal C1q upregulation. These data are compatible with the hypothesis that multiple receptors are involved in A&#x003b2; injury and signaling in neurons. Some lead to neuronal C1q induction, whereas other(s) lead to intraneuronal accumulation of A&#x003b2; and/or stimulation of microglia.</p></abstract></article-meta></front><body><sec><title>Introduction</title><p>Alzheimer's disease (AD) is the most common form of dementia in the elderly. Its main pathological features include extracellular amyloid beta (A&#x003b2;) deposition in plaques, neurofibrillary tangles (composed of hyperphosphorylated tau protein) in neurons, progressive loss of synapses and cortical/hippocampal neurons, and upregulation of inflammatory components including activated microglia and astrocytes and complement activation [<xref ref-type="bibr" rid="B1">1</xref>]. Although the contribution of abnormal phosphorylation and assembly of tau to AD dementia remains a focus of investigation, therapies that interfere with A&#x003b2; production, enhance its degradation, or cause its clearance from the central nervous system (CNS) have been the center of many studies in search of a cure for this disease.</p><p>Microglial cells, when activated, are believed to be responsible for much of the A&#x003b2; clearance through receptor-mediated phagocytosis [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Upon activation, microglia acquire features more characteristic of macrophages, including high phagocytic activity, increased expression of leukocyte common antigen (CD45), major histocompatibility complex (MHC) class II and costimulatory molecules B7, and secretion of proinflammatory substances [<xref ref-type="bibr" rid="B4">4</xref>]. In addition, phagocytic microglia also participate in the removal of degenerating neurons and synapses as well as A&#x003b2; deposits ([<xref ref-type="bibr" rid="B5">5</xref>], and reviewed in [<xref ref-type="bibr" rid="B6">6</xref>]). Thus, while some microglial functions are beneficial, the destructive effects of the production of toxins (such as nitric oxide, superoxide) and proinflammatory cytokines by activated microglia apparently overcome the protective functions in the chronic stage of neuroinflammation [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. <italic>In vitro </italic>studies have shown both protection and toxicity contributed by microglia in response to A&#x003b2; depending on the state of activation of microglia [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Correlative studies on AD patients and animal models of AD strongly suggest that accumulation of reactive microglia at sites of A&#x003b2; deposition contributes significantly to neuronal degeneration [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B11">11</xref>], although decreased microglia have been reported to be associated with both lowered and enhanced neurodegeneration in transgenic animals [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. A&#x003b2; itself is believed to initiate the accumulation and activation of microglia. However, recent reports provide evidence for neuron-microglial interactions in regulating CNS inflammation [<xref ref-type="bibr" rid="B14">14</xref>]. Nevertheless, the molecular mechanisms responsible for activation and regulation of microglia remain to be defined.</p><p>Complement proteins have been shown to be associated with A&#x003b2; plaques in AD brains, specifically those plaques containing the fibrillar form of the A&#x003b2; peptide [<xref ref-type="bibr" rid="B11">11</xref>]. Complement proteins are elevated in neurodegenerative diseases like AD, Parkinson's disease, and Huntington's disease as well as more restricted degenerative diseases such macular degeneration and prion disease [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. Microglia, astrocytes, and neurons in the CNS can produce most of the complement proteins upon stimulation. C1q, a subcomponent of C1, can directly bind to fibrillar A&#x003b2; and activate complement pathways [<xref ref-type="bibr" rid="B19">19</xref>], contributing to CNS inflammation [<xref ref-type="bibr" rid="B13">13</xref>]. In addition, C1q has been reported to be synthesized by neurons in several neurodegenerative diseases and animal injury models, generally as an early response to injury [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B23">23</xref>], possibly prior to the synthesis of other complement components.</p><p>Interestingly, C1q and, upon complement activation, C3 also can bind to apoptotic cells and blebs and promote ingestion of those dying cells [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. Elevated levels of apoptotic markers are present in AD brain tissue suggesting that many neurons undergo apoptosis in AD [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B29">29</xref>]. Excess glutamate, an excitatory neurotransmitter released from injured neurons and synapses, is one of the major factors that perturb calcium homeostasis and induce apoptosis in neurons [<xref ref-type="bibr" rid="B30">30</xref>]. Thus, it is reasonable to hypothesize that neuronal expression of C1q, as an early injury response, may serve a potentially beneficial role of facilitating the removal of apoptotic neurons or neuronal blebs [<xref ref-type="bibr" rid="B31">31</xref>] in diseases thereby preventing excess glutamate release, excitotoxicity, and the subsequent additional apoptosis.</p><p>We have previously reported that in rat hippocampal slice cultures treated with exogenous A&#x003b2;42, C1q expression was detected in pyramidal neurons following the internalization of A&#x003b2; peptide. This upregulation of neuronal C1q could be a response to injury from A&#x003b2; that would facilitate removal of dying cells. Concurrently, microglial activation was prominent upon A&#x003b2; treatment. In the present study, the relationship of A&#x003b2;-induced neuronal C1q production to microglia activation and A&#x003b2; uptake in slice cultures was investigated.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec sec-type="materials"><title>Materials</title><p>A&#x003b2; 1&#x02013;42, obtained from Dr. C. Glabe (UC, Irvine), was synthesized as previously described [<xref ref-type="bibr" rid="B32">32</xref>]. A&#x003b2; 10&#x02013;20 was purchased from California Peptide Research (Napa, CA). Lyophilized (in 10 mM HCl) A&#x003b2; peptides were solubilized in H<sub>2</sub>O and subsequently N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) was added to make a final concentration of 10 mM HEPES, 500 &#x003bc;M peptide. This solution was immediately diluted in serum-free medium and added to slices. Glycine-arginine-glycine-aspartic acid-serine-proline (RGD) peptide was purchased from Calbiochem (San Diego, CA). D-(-)-2-amino-5-phosphonovaleric acid (APV) was purchased from Sigma (St. Louis, MO). Both compounds were dissolved in sterile Hanks' balanced salt solution (HBSS) without glucose at 0.2 M and 5 mM, respectively, before diluted in serum-free medium. Antibodies used in experiments are listed in Table <xref ref-type="table" rid="T1">1</xref>; RT-PCR primers, synthesized by Integrated DNA Technologies (Coralville, IA), are listed in Table <xref ref-type="table" rid="T2">2</xref>. All other reagents were from Sigma unless otherwise noted.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Antibodies used in immunohistochemistry.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>antibody/antigen</bold></td><td align="left"><bold>concentration</bold></td><td align="left"><bold>source</bold></td></tr></thead><tbody><tr><td align="left">anti-rat C1q</td><td align="left">2 &#x003bc;g/ml</td><td align="left">M. Wing, Cambridge, UK</td></tr><tr><td align="left">OX-42 (CD11b/c)</td><td align="left">5 &#x003bc;g/ml</td><td align="left">BD/PharMingen, San Diego, CA</td></tr><tr><td align="left">ED-1</td><td align="left">3 &#x003bc;g/ml</td><td align="left">Chemicon, Temecula, CA</td></tr><tr><td align="left">anti-CD45</td><td align="left">0.5 &#x003bc;g/ml</td><td align="left">Serotec Inc, Raleigh, NC</td></tr><tr><td align="left">4G8 (A&#x003b2;)</td><td align="left">1 &#x003bc;g/ml</td><td align="left">Signet Pathology Systems, Dedham, MA</td></tr><tr><td align="left">6E10 (A&#x003b2;)</td><td align="left">0.5 &#x003bc;g/ml</td><td align="left">Signet Pathology Systems</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>PCR primers and cycling conditions for RT-PCR assay.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Gene</td><td align="left">Primer sequences</td><td align="left">Denaturation</td><td align="left">Annealing</td><td align="left">Extension</td><td align="left">cycle</td><td align="left">Ref</td></tr></thead><tbody><tr><td align="left">C1qB</td><td align="left">5'-cgactatgcccaaaacacct-3'<break/>5'-ggaaaagcagaaagccagtg-3'</td><td align="left">94&#x000b0;C 1 min</td><td align="left">60&#x000b0;C 1 min30 sec</td><td align="left">72&#x000b0;C 2 min</td><td align="left">35</td><td align="left">[61]</td></tr><tr><td align="left">MCSF</td><td align="left">5'-ccgttgacagaggtgaacc-3'<break/>5'-tccacttgtagaacaggaggc-3'</td><td align="left">92&#x000b0;C 30 sec</td><td align="left">58&#x000b0;C 1 min</td><td align="left">72&#x000b0;C 1 min30 sec</td><td align="left">35</td><td align="left">[62]</td></tr><tr><td align="left">CD40</td><td align="left">5'-cgctatggggctgcttgttgacag-3'<break/>5'-gacggtatcagtggtctcagtggc-3'</td><td align="left">94&#x000b0;C 30 sec</td><td align="left">58&#x000b0;C30 sec</td><td align="left">72&#x000b0;C 1 min</td><td align="left">30</td><td align="left">[63]</td></tr><tr><td align="left">&#x003b2;-actin</td><td align="left">5'-ggaaatcgtgcgtgacatta-3'<break/>5'-gatagagccaccaatccaca-3'</td><td align="left">94&#x000b0;C 30 sec</td><td align="left">60&#x000b0;C30 sec</td><td align="left">72&#x000b0;C 1 min</td><td align="left">25</td><td align="left">[61]</td></tr><tr><td align="left">IL-8</td><td align="left">5'-gactgttgtggcccgtgag-3'<break/>5'-ccgtcaagctctggatgttct-3'</td><td align="left">94&#x000b0;C 1 min</td><td align="left">56&#x000b0;C 1 min</td><td align="left">72&#x000b0;C 1 min</td><td align="left">39</td><td align="left">[64]</td></tr></tbody></table></table-wrap></sec><sec><title>Slice cultures</title><p>Hippocampal slice cultures were prepared according to the method of Stoppini et al [<xref ref-type="bibr" rid="B33">33</xref>] and as described in Fan and Tenner [<xref ref-type="bibr" rid="B34">34</xref>]. All experimental procedures were carried out under protocols approved by the University of California Irvine Institutional Animal Care and Use Committee. Slices prepared from hippocampi dissected from 10d-old Sprague Dawley rat pups (Charles River Laboratories, Inc., Wilmington, MA) were kept in culture for 10 to 11 days before treatment started. All reagents were added to serum-free medium (with 100 mg/L transferrin and 500 mg/L heat-treated bovine serum albumin) which was equilibrated at 37&#x000b0;C, 5% CO<sub>2 </sub>before addition to the slices. A&#x003b2; 1&#x02013;42 or A&#x003b2; 10&#x02013;20 was added to slice cultures as described previously [<xref ref-type="bibr" rid="B34">34</xref>]. Briefly, peptide was added to cultures in serum-free medium at 10 or 30 &#x003bc;M. After 7 hours, the peptide was diluted with the addition of an equal amount of medium containing 20% heat-inactivated horse serum. Fresh peptide was applied for each day of treatment. Controls were treated the same way except without peptide. RGD or APV was added to the slice cultures at the same time as A&#x003b2; 42.</p></sec><sec><title>Immunohistochemistry</title><p>At the end of the treatment period, media was removed, the slices were washed with serum-free media and subjected to trypsinization as previously described [<xref ref-type="bibr" rid="B34">34</xref>] for 15 minutes at 4&#x000b0;C to remove cell surface associated, but not internalized, A&#x003b2;. After washing, slices were fixed and cut into 20 &#x003bc;m sections for immunohistochemistry or extracted for protein or RNA analysis as described in Fan and Tenner [<xref ref-type="bibr" rid="B34">34</xref>]. Primary antibodies (anti-A&#x003b2; antibody 4G8 or 6E10; rabbit anti rat C1q antibody; CD45 (leukocyte common antigen, microglia), OX42 (CD11b/c, microglia), or ED1 (rat microglia/macrophage marker), or their corresponding control IgGs were applied at concentrations listed in Table <xref ref-type="table" rid="T1">1</xref>, followed by biotinylated secondary antibody (Vector Labs, Burlingame, CA) and finally FITC- or Cy3-conjugated streptavidin (Jackson ImmunoResearch Laboratories, West Grove, PA). Slides were examined on an Axiovert 200 inverted microscope (Carl Zeiss Light Microscopy, G&#x000f6;ttingen, Germany) with AxioCam (Zeiss) digital camera controlled by AxioVision program (Zeiss). Images (of the entire CA1-CA2 region of hippocampus) were analyzed with KS 300 analysis program (Zeiss) to obtain the percentage area occupied by positive immunostaining in a given field.</p></sec><sec><title>ELISA</title><p>Slices were homogenized in ice-cold extraction buffer (10 mM triethanolamine, pH 7.4, 1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 0.15 M NaCl, 0.3% NP-40) containing protease inhibitors pepstatin (2 &#x003bc;g/ml), leupeptin (10 &#x003bc;g/ml), aprotinin (10 &#x003bc;g/ml), and PMSF (1 mM). Protein concentration was determined by BCA assay (Pierce, Rockford, IL) using BSA provided for the standard curve.</p><p>An ELISA for rat C1q was adapted from Tenner and Volkin [<xref ref-type="bibr" rid="B35">35</xref>] with some modifications as previously described [<xref ref-type="bibr" rid="B34">34</xref>].</p></sec><sec><title>RNA preparation and RT-PCR</title><p>Total RNA from cultures was isolated using the Trizol reagent (Life Technologies, Grand Island, NY) according to the manufacturer's instructions. RNA was treated with RNase-free DNase (Fisher, Pittsburgh, PA) to remove genomic DNA contamination. Each RNA sample was extracted from 3 to 5 hippocampal organotypic slices in the same culture insert. The reverse transcription (RT) reaction conditions were 42&#x000b0;C for 50 min, 70&#x000b0;C for 15 min. Tubes were then centrifuged briefly and held at 4&#x000b0;C. Primer sequences and PCR conditions are listed in Table <xref ref-type="table" rid="T2">2</xref>. PCR products were electrophoresed in 2% agarose gel in TAE buffer and visualized with ethidium bromide luminescence. To test for differences in total RNA concentration among samples, mRNA level for rat &#x003b2;-actin were also determined by RT-PCR. Results were quantified using NIH image software [<xref ref-type="bibr" rid="B36">36</xref>] by measuring DNA band intensity from digital images taken on GelDoc (BIO-RAD) with Quantity One program.</p></sec></sec><sec><title>Results</title><sec><title>NMDA receptor antagonist APV inhibits A&#x003b2;42 uptake and A&#x003b2;42-induced microglial activation and neuronal C1q production</title><p>We have previously reported that C1q was detected in cells positive for neuronal markers and that microglial cells were activated in slices following A&#x003b2;42 ingestion [<xref ref-type="bibr" rid="B34">34</xref>]. Lynch and colleagues have shown that APV, a specific NMDA glutamate receptor antagonist, was able to block A&#x003b2;42 uptake by hippocampal neurons in slice cultures [<xref ref-type="bibr" rid="B37">37</xref>]. This provided a mechanism to down-modulate the A&#x003b2;42 internalization and test the effect on induction of C1q synthesis in neurons. Slices were treated with no peptide, 50 &#x003bc;M APV, 30 &#x003bc;M A&#x003b2;42, or 30 &#x003bc;M A&#x003b2;42 + 50 &#x003bc;M APV for 3 days with fresh reagents added daily. Cultures were collected and processed as described in Materials and Methods. Similar to reported previously, addition of exogenous A&#x003b2;42 resulted in A&#x003b2; uptake by hippocampal neurons, induction of C1q synthesis in neurons, and activation of microglial cells (Figure <xref ref-type="fig" rid="F1">1d, e, f</xref> compared with <xref ref-type="fig" rid="F1">1a, b, c</xref>). As anticipated, A&#x003b2;42 uptake in neurons detected by both 4G8 (Figure <xref ref-type="fig" rid="F1">1g</xref>) and 6E10 (data not shown) was inhibited by APV co-treatment. Neuronal C1q immunoreactivity was also inhibited when APV was added to A&#x003b2;42 treated slices (Figure <xref ref-type="fig" rid="F1">1h</xref>). A&#x003b2;42-triggered microglial activation, assessed by upregulation of antigens detected by anti-CD45 (Figure <xref ref-type="fig" rid="F1">1i</xref> vs. <xref ref-type="fig" rid="F1">1f</xref>), OX42 and ED1 (data not shown) was also fully diminished by APV. To quantify the immunohistochemistry results, images were taken from the entire CA1-CA2 region of each immunostained hippocampal section and averaged. Image analysis further substantiated the reduction in A&#x003b2; uptake, C1q synthesis and microglial activation (Figure <xref ref-type="fig" rid="F1">1j</xref>). C1q gene expression at mRNA and protein levels was also assessed by RT-PCR and ELISA, respectively. Results showed decrease of C1q mRNA and protein in slice extracts treated with 30 &#x003bc;M A&#x003b2;42 + APV, compared to 30 &#x003bc;M A&#x003b2;42 alone (Figure <xref ref-type="fig" rid="F2">2a</xref> and <xref ref-type="fig" rid="F2">2b</xref>, n = 2).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>APV inhibited A&#x003b2; uptake, neuronal C1q production, and microglial activation. Slices were treated with no peptide (a, b, c), 30 &#x003bc;M A&#x003b2; 42 (d, e, f), or 30 &#x003bc;M A&#x003b2; 42 + 50 &#x003bc;M APV (g, h, i) for 3 days with fresh reagents added daily. Immunohistochemistry for A&#x003b2; (4G8, a, d, g), C1q (anti-rat C1q, b, e, h), and microglia (CD45, c, f, i) was performed on fixed and sectioned slices. Scale bar = 50 &#x003bc;m. Results are representative of three separately performed experiments. j. Immunoreactivity of A&#x003b2; (open bar), C1q (black bar), or CD45 (striped bar) was quantified as described in Materials and Methods. Values are the mean &#x000b1; SD (error bars) from images taken from 8 slices (2 sections per slice) in 3 independent experiments (* p &#x0003c; 0.0001 compared to A&#x003b2;, Anova single factor test).</p></caption><graphic xlink:href="1742-2094-2-1-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Inhibition of A&#x003b2;-induced C1q synthesis by APV. a. C1q and &#x003b2;-actin mRNAs were assessed by RT-PCR in slices after 3 days of no peptide, 30 &#x003bc;M A&#x003b2;, or 30 &#x003bc;M A&#x003b2; + 50 &#x003bc;M APV treatment. Results are from one experiment representative of two independent experiments. b. Slices were treated with no peptide (open bar), 30 &#x003bc;M A&#x003b2; (black bar), or 30 &#x003bc;M A&#x003b2; + 50 &#x003bc;M APV (striped bar) daily for 3 days. 3 or 4 slices that had received same treatment were pooled, extracted and proteins analyzed by ELISA. Data are presented as percentage of control in ng C1q/mg total protein (mean &#x000b1; SD of three independent experiments, **p = 0.01 compared to A&#x003b2;, one-tailed paired t-test).</p></caption><graphic xlink:href="1742-2094-2-1-2"/></fig></sec><sec><title>Integrin receptor antagonist GRGDSP (RGD) peptide enhances A&#x003b2;42 uptake and A&#x003b2;42-induced microglial activation and neuronal C1q expression</title><p>It has been shown that an integrin receptor antagonist peptide, GRGDSP (RGD), can enhance A&#x003b2; ingestion by neurons in hippocampal slice cultures [<xref ref-type="bibr" rid="B37">37</xref>]. Therefore, we adopted this experimental manipulation as an alternative approach to modulate the level of A&#x003b2; uptake in neurons and assess the correlation between A&#x003b2; ingestion and neuronal C1q expression. Slices were treated with no peptide, 2 mM RGD, 10 &#x003bc;M A&#x003b2;42, or 10 &#x003bc;M A&#x003b2;42 + 2 mM RGD for 3 days with fresh peptides added daily. At the end of treatments, slices were collected and processed.</p><p>Addition of RGD peptide by itself did not result in neuronal C1q induction or microglial activation (CD45) compared to no treatment control, as assessed by immunostaining (data not shown). While greater ingestion was seen at 30 &#x003bc;M (Figure <xref ref-type="fig" rid="F1">1d, e, f</xref>), addition of 10 &#x003bc;M A&#x003b2; shows detectable A&#x003b2; ingestion, C1q expression, and microglial activation (Figure <xref ref-type="fig" rid="F3">3d, e, f</xref> compared with <xref ref-type="fig" rid="F3">3a, b, c</xref>). The lower concentration of A&#x003b2; was chosen for these experiments to ensure the detection of potentiation of uptake (vs. a saturation of uptake at higher A&#x003b2;42 concentrations). When RGD was provided in addition to 10 &#x003bc;M A&#x003b2;42, A&#x003b2; immunoreactivity in neurons with antibody 4G8 (Figure <xref ref-type="fig" rid="F3">3g</xref> vs. <xref ref-type="fig" rid="F3">3d</xref>) and 6E10 (similar results, data not shown), neuronal C1q expression (Figure <xref ref-type="fig" rid="F3">3h</xref> vs. <xref ref-type="fig" rid="F3">3e</xref>), and CD45 (Figure <xref ref-type="fig" rid="F3">3i</xref> vs. <xref ref-type="fig" rid="F3">3f</xref>) upregulation in microglia triggered by A&#x003b2;42, were significantly enhanced. Enhanced microglial activation was also detected with OX42 and ED1 antibodies (data not shown). Quantification by image analysis (Figure <xref ref-type="fig" rid="F3">3j</xref>) definitively demonstrated that the increased accumulation of A&#x003b2; in neurons, microglial activation, and induction of neuronal C1q synthesis in the presence of RGD. RT-PCR (Figure <xref ref-type="fig" rid="F4">4a</xref>) and ELISA (Figure <xref ref-type="fig" rid="F4">4b</xref>) further demonstrated that both mRNA and protein expression of C1q was enhanced by RGD. Thus, under the conditions tested, both neuronal C1q synthesis and microglial activation are coordinately affected when the internalization of A&#x003b2; is modulated negatively by APV or positively by RGD.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>RGD enhanced A&#x003b2; uptake, neuronal C1q expression, and microglial activation. Hippocampal slices were treated with no peptide (a, b, c), 10 &#x003bc;M A&#x003b2; 42 (d, e, f), or 10 &#x003bc;M A&#x003b2; 42 + 2 mM RGD (g, h, i) for 3 days with fresh peptides added daily. Immunohistochemistry for A&#x003b2; (4G8, a, d, g), C1q (anti-rat C1q, b, e, h), and microglia (CD45, c, f, i) was performed on fixed slice sections. Scale bar = 50 &#x003bc;m. Results are representative of three separately performed experiments. j. Immunoreactivities of A&#x003b2; (open bar), C1q (black bar), or CD45 (striped bar) were quantified as described in Materials and Methods. Values are the mean &#x000b1; SD (error bars) from images taken from 8 slices (2 sections per slice) in 3 independent experiments (* p &#x0003c; 0.0001, compared to A&#x003b2;, Anova single factor test).</p></caption><graphic xlink:href="1742-2094-2-1-3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Enhancement of A&#x003b2;-induced C1q synthesis by RGD. a. C1q and &#x003b2;-actin mRNAs were assessed by RT-PCR in slices after 3 days of no peptide, 10 &#x003bc;M A&#x003b2;, or 10 &#x003bc;M A&#x003b2; + 2 mM RGD treatment. Results are from one experiment representative of two independent experiments. b. Slices were treated with no peptide (open bar), 10 &#x003bc;M A&#x003b2; (black bar), or 10 &#x003bc;M A&#x003b2; + 2 mM RGD (striped bar) daily for 3 days. 3 or 4 slices that had received same treatment were pooled, extracted and proteins analyzed by ELISA. Data are presented as percentage of control in ng C1q/mg total protein (mean &#x000b1; SD of three independent experiments, **p = 0.06 compared to A&#x003b2;, one-tailed paired t-test).</p></caption><graphic xlink:href="1742-2094-2-1-4"/></fig></sec><sec><title>A&#x003b2;10&#x02013;20 blocks A&#x003b2;42 induced microglial activation but triggers C1q synthesis in hippocampal neurons</title><p>Data reported by Giulian et al suggests that residues 13&#x02013;16, the HHQK domain in human A&#x003b2; peptide, mediate A&#x003b2;-microglia interaction [<xref ref-type="bibr" rid="B38">38</xref>]. To investigate the effect of HHQK peptides in this slice culture system, rat hippocampal slices were treated with no peptide, 10 &#x003bc;M A&#x003b2;42, 10 &#x003bc;M A&#x003b2;42 + 30 &#x003bc;M A&#x003b2;10&#x02013;20, or 30 &#x003bc;M A&#x003b2;10&#x02013;20 for 3 days with fresh peptides added daily. Sections were immunostained for A&#x003b2;, C1q, and microglia. A&#x003b2; immunoreactivity was significantly reduced in the A&#x003b2;42 +A&#x003b2;10&#x02013;20 treated tissues compared to the A&#x003b2;42 alone treatment (Figure <xref ref-type="fig" rid="F5">5g</xref> vs. <xref ref-type="fig" rid="F5">5d</xref>). A&#x003b2;10&#x02013;20 alone-treated slices lacked detectable immunopositive cells with either 4G8 or 6E10 anti-A&#x003b2; antibody (Figure <xref ref-type="fig" rid="F5">5j</xref> and data not shown). Furthermore, as anticipated [<xref ref-type="bibr" rid="B38">38</xref>], when A&#x003b2;10&#x02013;20 was present, microglial activation by A&#x003b2;42 as assessed by level of CD45, OX42, and ED1, was significantly reduced (Figure <xref ref-type="fig" rid="F5">5i</xref> vs. <xref ref-type="fig" rid="F5">5f</xref> and data not shown). Image analysis confirmed the inhibition of A&#x003b2; uptake (Figure <xref ref-type="fig" rid="F5">5m</xref>, open bars) and microglial activation (Figure <xref ref-type="fig" rid="F5">5m</xref>, striped bars) by the HHQK-containing A&#x003b2;10&#x02013;20 peptide. However, production of C1q in neurons treated with A&#x003b2;42 was not inhibited by A&#x003b2;10&#x02013;20 (Figure <xref ref-type="fig" rid="F5">5h</xref> vs. <xref ref-type="fig" rid="F5">5e</xref>). In fact, with A&#x003b2;10&#x02013;20 alone, neurons were induced to express C1q to a similar level as A&#x003b2;42 (Figure <xref ref-type="fig" rid="F5">5k</xref>). The sustained C1q induction by A&#x003b2;10&#x02013;20 was confirmed by RT-PCR for C1q with mRNAs extracted from slices (Figure <xref ref-type="fig" rid="F6">6a</xref>).</p><fig position="float" id="F5"><label>Figure 5</label><caption><p>A&#x003b2;10&#x02013;20 blocked A&#x003b2;42 uptake, microglial activation, but not neuronal C1q induction. Slices were treated with no peptide (a, b, c), 10 &#x003bc;M A&#x003b2; 42 (d, e, f), 10 &#x003bc;M A&#x003b2; 42 + 30 &#x003bc;M A&#x003b2; 10&#x02013;20 (g, h, i) or 30 &#x003bc;M A&#x003b2; 10&#x02013;20 (j, k, l) for 3 days with fresh peptides added daily. Immunohistochemistry for A&#x003b2; (4G8, a, d, g, j), C1q (anti-rat C1q, b, e, h, k), and microglia (CD45, c, f, i, l) was performed on fixed and sectioned slices. Results are representative of three independent experiments. Scale bar = 50 &#x003bc;m. m. Immunoreactivities of A&#x003b2; (open bar), C1q (black bar), or CD45 (striped bar) were quantified as described in Materials and Methods. Values are the mean &#x000b1; SD (error bars) from images taken from 8 slices (2 sections per slice) in 3 independent experiments. Microglial activation by A&#x003b2;42 was significantly inhibited by A&#x003b2;10&#x02013;20 (* p &#x0003c; 0.0001, compared to either A&#x003b2;42 + A&#x003b2;10&#x02013;20 or A&#x003b2;10&#x02013;20, Anova single factor test).</p></caption><graphic xlink:href="1742-2094-2-1-5"/></fig><fig position="float" id="F6"><label>Figure 6</label><caption><p>a. A&#x003b2;10&#x02013;20 inhibited A&#x003b2;42-induced C1q and CD40 mRNA elevation, but not that of MCSF. C1q, MCSF, CD40, and &#x003b2;-actin mRNAs were assessed by RT-PCR in slices treated for 3 days with no peptide, 10 &#x003bc;M A&#x003b2; 42, 30 &#x003bc;M A&#x003b2; 10&#x02013;20, or 10 &#x003bc;M A&#x003b2; 42 + 30 &#x003bc;M A&#x003b2; 10&#x02013;20. Results are from one experiment representative of two independent experiments. b. APV blocked MCSF, CD40, and IL-8 mRNA induction triggered by A&#x003b2;42. RT-PCR for MCSF, CD40, IL-8, and &#x003b2;-actin were performed on RNA extracted from slices treated with no peptide (control), 30 &#x003bc;M A&#x003b2; 42, or 30 &#x003bc;M A&#x003b2;42 + 50 &#x003bc;M APV for 3 days. Results are from one experiment representative of two separate experiments.</p></caption><graphic xlink:href="1742-2094-2-1-6"/></fig></sec><sec><title>CD40, IL-8, and MCSF mRNAs are induced by A&#x003b2;42 and differentially regulated by A&#x003b2;10&#x02013;20 and APV</title><p>It is known that activated microglia cells can produce pro-inflammatory cytokines, chemokines, and nitric oxide, as well as higher expression of co-stimulatory molecules like CD40 and B7 [<xref ref-type="bibr" rid="B39">39</xref>]. Many of those proteins have been shown to be upregulated in microglia stimulated by A&#x003b2; in cell culture and <italic>in vivo </italic>[<xref ref-type="bibr" rid="B40">40</xref>]. Semi-quantitative reverse transcriptase PCR technique was used to determine how certain inducible activation products were modified in slice cultures stimulated with exogenous A&#x003b2;42 and in the presence of A&#x003b2;10&#x02013;20 or APV. Rat slices were treated with 30 &#x003bc;M A&#x003b2;42 +/-APV or 10 &#x003bc;M A&#x003b2;42 +/- 30 &#x003bc;M A&#x003b2;10&#x02013;20 for 3 days before mRNAs were extracted from tissues. LPS, was added at 150 ng/ml for 24 hr, served as positive control, with positive detection for all molecules tested (data not shown).</p><p>RT-PCR revealed that mRNAs for CD40 and IL-8 were enhanced in A&#x003b2; treated slice cultures relative to the control after 3 days (Figure <xref ref-type="fig" rid="F6">6a</xref> and <xref ref-type="fig" rid="F6">6b</xref>). Both A&#x003b2;10&#x02013;20 and APV inhibited A&#x003b2;42-triggered upregulation of CD40 (Figure <xref ref-type="fig" rid="F6">6a</xref> and <xref ref-type="fig" rid="F6">6b</xref>), consistent with the inhibition of microglial activation by both A&#x003b2;10&#x02013;20 and APV assessed by immunohistochemistry. APV also blocked A&#x003b2;42-induced IL-8 expression (Figure <xref ref-type="fig" rid="F6">6b</xref>), as did A&#x003b2;10&#x02013;20 (data not shown).</p><p>Macrophage-colony stimulating factor (MCSF), a proinflammatory mediator for microglial proliferation and activation, has been shown to be expressed by neurons upon A&#x003b2; stimulation [<xref ref-type="bibr" rid="B41">41</xref>]. The expression of MCSF was induced in slice culture by A&#x003b2; treatment by Day 3 (Figure <xref ref-type="fig" rid="F6">6a</xref> and <xref ref-type="fig" rid="F6">6b</xref>) and this increase was blocked by the presence of APV (Figure <xref ref-type="fig" rid="F6">6b</xref>). In contrast, A&#x003b2;10&#x02013;20 did not alter the A&#x003b2;42-triggered MCSF induction (Figure <xref ref-type="fig" rid="F6">6a</xref>), suggesting that MCSF may be required for microglial activation, but alone is not sufficient to induce that activation.</p></sec></sec><sec><title>Discussion</title><p>Previously, it has been shown that A&#x003b2; is taken up by pyramidal neurons in hippocampal slice culture and that the synthesis of complement protein C1q is induced in neurons [<xref ref-type="bibr" rid="B34">34</xref>]. Here we demonstrate that blocking of A&#x003b2;42 accumulation in neurons by NMDA receptor antagonist APV and increasing A&#x003b2;42 ingestion by integrin antagonist RGD is accompanied by inhibition and elevation in neuronal C1q expression, respectively. However, A&#x003b2;10&#x02013;20, which markedly inhibits A&#x003b2;42 accumulation in pyramidal neurons, does not have any inhibitory effect on neuronal C1q expression. Thus, intraneuronal accumulation of A&#x003b2; is not necessary for A&#x003b2;-mediated induction of neuronal C1q synthesis.</p><p>Since A&#x003b2;10&#x02013;20 alone can induce a level of C1q expression in neurons comparable to A&#x003b2;42, it is hypothesized that amino acids 10&#x02013;20 in A&#x003b2; peptide contain the sequence that is recognized by at least one A&#x003b2; receptor. It was reported by Giulian et al. that the HHQK domain (residues 13&#x02013;16) in A&#x003b2; is critical for A&#x003b2;-microglia interaction and activation of microglia, as they demonstrated that small peptides containing HHQK suppress microglial activation and A&#x003b2;-induced microglial mediated neurotoxicity [<xref ref-type="bibr" rid="B38">38</xref>]. We have previously reported that rat A&#x003b2;42, which differs in 3 amino acids from human A&#x003b2;42, including 2 in the 10&#x02013;20 region and 1 in the HHQK domain, was internalized and accumulated in neurons but failed to induce neuronal C1q expression [<xref ref-type="bibr" rid="B34">34</xref>]. This is consistent with the hypothesis that a specific A&#x003b2; interaction (either neuronal or microglial), presumably via the HHQK region of the A&#x003b2; peptide, but not intracellular A&#x003b2; accumulation, can lead to neuronal C1q induction in hippocampal neurons.</p><p>Neurons are the major type of cells that accumulate exogenous A&#x003b2; in slice cultures. Microglial activation, as assessed by CD45, OX42, and ED1, was increased with enhanced neuronal A&#x003b2;42 uptake and inhibited when A&#x003b2;42 uptake was blocked by APV or A&#x003b2;10&#x02013;20 in this slice culture system. These data would be consistent with a model in which neurons, upon internalization of A&#x003b2; peptide, secrete molecules to modulate microglial activation [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>] (Figure <xref ref-type="fig" rid="F7">7</xref>, large arrows). Synthesis and release of those molecules may require the intracellular accumulation of A&#x003b2; since blocking intraneuronal A&#x003b2; accumulation always blocked microglial activation. The finding that treatment with A&#x003b2;10&#x02013;20 alone did not result in intraneuronal A&#x003b2; immunoreactivity or microglial activation, while rat A&#x003b2;42, which did accumulate within neurons, induced activation of microglial cells, is consistent with this hypothesis. It should be noted that an absence of A&#x003b2; immunoreactivity in A&#x003b2;10&#x02013;20 treated slices does not exclude the possibility that A&#x003b2;10&#x02013;20 was ingested but soon degraded by cells, and thus accumulation of A&#x003b2; rather than ingestion alone may be necessary to induce secretion of microglia activating molecules from neurons. Giulian et al. reported that the HHQK region alone was not able to activate microglia [<xref ref-type="bibr" rid="B38">38</xref>]. Thus, A&#x003b2;10&#x02013;20 might block microglial activation by competing with A&#x003b2;42 for direct microglial binding, as well as by blocking uptake and accumulation of A&#x003b2; in neurons.</p><fig position="float" id="F7"><label>Figure 7</label><caption><p>Model of A&#x003b2; interaction with neurons and microglia in slice cultures. Exogenous A&#x003b2; peptide interacts with neuronal receptors leads to at least two separate consequences, in one of which C1q expression is upregulated in neurons. A second receptor mediates the secretion of certain modulatory molecules, which lead to microglial activation involving the expression of CD45, CR3, CD40, and IL-8. This does not exclude the direct interactions of A&#x003b2; with receptor(s) on microglia that may also contribute to microglial activation.</p></caption><graphic xlink:href="1742-2094-2-1-7"/></fig><p>Activated glial cells, especially microglia, are major players in the neuroinflammation seen in of Alzheimer's disease [<xref ref-type="bibr" rid="B43">43</xref>]. Microglial cells can be activated by A&#x003b2; and produce proinflammatory cytokines, nitric oxide, superoxide, and other potentially neurotoxic substances <italic>in vitro</italic>, although the state of differentiation/ activation of microglia and the presence of other modulating molecules is known to influence this stimulation [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. "Activated" microglia also become more phagocytic and can partially ingest and degrade amyloid deposits in brain. This leads many to hypothesize that there are multiple subsets of "activated" microglia, each primed to function in a specific but distinct way [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B43">43</xref>].</p><p>In hippocampal slice cultures, we and others have shown that A&#x003b2;42 triggered microglial activation as assessed by immunohistochemical detection of CR3 (OX42), and cathepsin D [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. Several chemokines, including macrophage inflammatory protein-1 (MIP-1&#x003b1;, MIP-1&#x003b2;), monocyte chemotactic protein (MCP-1), and interleukin 8 (IL-8), have been reported to increase in Alzheimer's disease patients or cell cultures treated with A&#x003b2; [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. CD40, a co-stimulatory molecule, is also upregulated in A&#x003b2;-treated microglia [<xref ref-type="bibr" rid="B10">10</xref>]. In this study, similar to reports of cultured microglia, immunoreactivity of CD45 was found increased on microglia in A&#x003b2;42 treated slice cultures, and CD40 and IL-8 messenger RNAs were elevated after A&#x003b2;42 exposure. As expected, CD40 and IL-8 mRNA induction was blocked whenever immunohistochemistry analysis showed the inhibition of microglial activation. [We did not observe change in MIP-1&#x003b1;, 1&#x003b2; mRNAs in slice culture with A&#x003b2;42 treatment, and MCP-1 was too low to be detected with or without A&#x003b2; stimulation although it was detectable in LPS treated slices (data not shown).]</p><p>The data presented thus far suggest the hypothesis that neurons, upon uptake and accumulation of A&#x003b2;, release certain substances that activate microglia. One possible candidate of those neuron-produced substances is MCSF, which has been reported to be induced in neuronal cultures upon A&#x003b2; stimulation [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B46">46</xref>], and is known to be able to trigger microglial activation [<xref ref-type="bibr" rid="B47">47</xref>]. Indeed, MCSF mRNA was found to increase after 3 days of A&#x003b2; treatment (Figure <xref ref-type="fig" rid="F6">6a</xref> and <xref ref-type="fig" rid="F6">6b</xref>). The diminished MCSF signal with the addition of APV and coordinate lack of microglial activation is consistent with a proposed role of activating microglia by MCSF produced by stimulated neurons. However, in the presence of A&#x003b2;10&#x02013;20, MCSF induction was unaltered, though microglial activation was inhibited. Thus, MCSF alone does not lead to the upregulation of the above-mentioned microglial activation markers.</p><p>In this organotypic slice culture, no significant neuronal damage was observed in 3 day treatment with A&#x003b2; at concentrations that have been reported to cause neurotoxicity in cell cultures. One possible explanation is that the peptide has to penetrate the astrocyte layer surrounding the tissue to reach the multiple layers of neurons. Thus, the effective concentration of A&#x003b2; on neurons is certainly much lower than the added concentration. A&#x003b2; failing to induce neurotoxicity in slices to the same extent as in cell cultures may also indicate the loss of certain protective mechanisms in isolated cells. A distinct advantage of the slice culture model is that the tissue contains all of the cell types present in brain, the cells are all at the same developmental stage, and cells may communicate in similar fashion as <italic>in vivo</italic>.</p><p>Our data demonstrating distinct pathways for the induction of neuronal C1q and the activation of microglial by amyloid peptides suggest the involvement of multiple A&#x003b2; receptors on multiple cell types in response to A&#x003b2; (Figure <xref ref-type="fig" rid="F7">7</xref>, model) and possibly in Alzheimer's disease progression. This multiple-receptor mechanism is supported by reports suggesting many proteins/complexes can mediate the A&#x003b2; interaction with cells [<xref ref-type="bibr" rid="B48">48</xref>]. These include, but not limited to, the alpha7nicotinic acetylcholine receptor (alpha7nAChR), the P75 neurotrophin receptor (P75NTR) on neurons, the scavenger receptors and heparan sulfate proteoglycans on microglia, as well as receptor for advanced glycosylation end-products (RAGE) and integrins on both neurons and microglia (Figure <xref ref-type="fig" rid="F7">7</xref>). Several signaling pathways have been implicated in specific A&#x003b2;-receptor interactions [<xref ref-type="bibr" rid="B49">49</xref>-<xref ref-type="bibr" rid="B51">51</xref>]. However, it is not known which receptors are required for induction of C1q in neurons. In addition, as of yet the function of neuronal C1q has not been determined. Previous reports from our lab have shown that C1q is associated with hippocampal neurons in AD cases but not normal brain [<xref ref-type="bibr" rid="B52">52</xref>], and the fact that it is synthesized by the neurons has been documented by others [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B53">53</xref>]. In addition, C1q was prominently expressed in a preclinical case of AD (significant diffuse amyloid deposits, with no plaque associated C1q, and no obvious cognitive disorder) and is expressed in other situations of "stress" or injury in the brain [<xref ref-type="bibr" rid="B54">54</xref>-<xref ref-type="bibr" rid="B58">58</xref>]. Indeed, overexpression of human cyclooxygenase-2 in mice leads to C1q synthesis in neurons and inhibition of COX-2 activity abrogates C1q induction. These data suggest that in addition to the facilitation of phagocytosis by microglia [<xref ref-type="bibr" rid="B59">59</xref>,<xref ref-type="bibr" rid="B60">60</xref>] (particularly of dead cells or neuronal blebs), the induction of C1q may be an early response of neurons to injury or regulation of an inflammatory response, consistent with a role in the progression of neurodegeneration in AD. Whether and how the neuronal C1q production affects the survival of neurons is still under investigation. Identifying the receptors responsible for neuronal C1q induction may be informative in understanding the role of C1q in neurons in injury and disease.</p></sec><sec><title>Conclusions</title><p>In summary, induction of C1q expression in hippocampal neurons by exogenous A&#x003b2;42 is dependent upon specific cellular interactions with A&#x003b2; peptide that require HHQK region-containing sequence, but does not require intraneuronal accumulation of A&#x003b2; or microglial activation. Thus, induction of neuronal C1q synthesis may be an early response to injury to facilitate clearance of damaged cells, while modulating inflammation and perhaps facilitating repair. Microglial activation in slice culture involves the induction of CD45, CD40, CR3, and IL-8, which correlates with intraneuronal accumulation of A&#x003b2;, indicating contribution of factors released by neurons upon A&#x003b2; exposure. MCSF may be one of those stimulatory factors, though by itself MCSF cannot fully activate microglia.</p><p>Removal of A&#x003b2; to prevent deposition and of cellular debris to avoid excitotoxicity would be a beneficial role of microglial activation in AD. However, activated microglia also produce substances that are neurotoxic. Therefore, the goal of modulating the inflammatory response in neurodegenerative diseases like AD is to enhance the phagocytic function of glial cells and inhibit the production of proinflammatory molecules. Being able to distinguish in the slice system C1q expression (which has been shown to facilitate phagocytosis of apoptotic cells in other systems [<xref ref-type="bibr" rid="B24">24</xref>]) from microglial activation suggests a plausible approach to reach that goal <italic>in vivo</italic>.</p></sec><sec><title>List of abbreviations</title><p>A&#x003b2;: amyloid beta; AD: Alzheimer's disease; APV: D-(-)-2-amino-5-phosphonovaleric acid; BSA: bovine serum albumin; GRGDSP (RGD): glycine-arginine-glycine-aspartic acid-serine-proline; HBSS: Hanks' balanced salt solution; HEPES: N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; MCSF: macrophage colony stimulating factor; NMDA: N-methyl-D-aspartic acid; PMSF: phenylmethylsulfonylfluoride; TAE: triethanolamine.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>RF cultured and processed the tissue, performed all experiments (immunohistochemistry, ELISA, PCR and others), analyzed the data, and drafted the manuscript. AJT contributed to the design of the study, guided data interpretation and presentation and edited the manuscript.</p></sec></body><back><ack><sec><title>Acknowledgments</title><p>This work is supported by NIH NS 35144 and P50 AG16573. The authors thank Dr. Saskia Milton and Dr. Charles Glabe for providing the synthetic human A&#x003b2; peptide, and Dr. Maria Fonseca, Dr. Ming Li, and Karntipa Pisalyaput for their review of this manuscript.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattson</surname><given-names>MP</given-names></name></person-group><article-title>Pathways towards and away from Alzheimer's disease</article-title><source>Nature</source><year>2004</year><volume>430</volume><fpage>631</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">15295589</pub-id><pub-id pub-id-type="doi">10.1038/nature02621</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>SD</given-names></name><name><surname>Yang</surname><given-names>AJ</given-names></name><name><surname>Margol</surname><given-names>L</given-names></name><name><surname>Garzon-Rodriguez</surname><given-names>W</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name></person-group><article-title>Complement component C1q modulates the phagocytic behavior of microglia</article-title><source>Exp Neurol</source><year>2000</year><volume>161</volume><fpage>127</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">10683279</pub-id><pub-id pub-id-type="doi">10.1006/exnr.1999.7260</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Strohmeyer</surname><given-names>R</given-names></name><name><surname>Kovelowski</surname><given-names>CJ</given-names></name><name><surname>Li</surname><given-names>R</given-names></name></person-group><article-title>Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide</article-title><source>Glia</source><year>2002</year><volume>40</volume><fpage>260</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">12379913</pub-id><pub-id pub-id-type="doi">10.1002/glia.10153</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>PT</given-names></name><name><surname>Soma</surname><given-names>LA</given-names></name><name><surname>Lavi</surname><given-names>E</given-names></name></person-group><article-title>Microglia in diseases of the central nervous system</article-title><source>Ann Med</source><year>2002</year><volume>34</volume><fpage>491</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">12553488</pub-id><pub-id pub-id-type="doi">10.1080/078538902321117698</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>MA</given-names></name><name><surname>Dailey</surname><given-names>ME</given-names></name></person-group><article-title>Diverse microglial motility behaviors during clearance of dead cells in hippocampal slices</article-title><source>Glia</source><year>2004</year><volume>46</volume><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">15042586</pub-id><pub-id pub-id-type="doi">10.1002/glia.10362</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Andrea</surname><given-names>MR</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name><name><surname>Ard</surname><given-names>MD</given-names></name></person-group><article-title>The microglial phagocytic role with specific plaque types in the Alzheimer disease brain</article-title><source>Neurobiol Aging</source><year>2004</year><volume>25</volume><fpage>675</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">15172747</pub-id><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2003.12.026</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combs</surname><given-names>CK</given-names></name><name><surname>Karlo</surname><given-names>JC</given-names></name><name><surname>Kao</surname><given-names>SC</given-names></name><name><surname>Landreth</surname><given-names>GE</given-names></name></person-group><article-title>beta-Amyloid stimulation of microglia and monocytes results in TNFalpha- dependent expression of inducible nitric oxide synthase and neuronal apoptosis</article-title><source>J Neurosci</source><year>2001</year><volume>21</volume><fpage>1179</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">11160388</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Curb</surname><given-names>JD</given-names></name><name><surname>Masaki</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>LR</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name></person-group><article-title>Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study</article-title><source>Ann Neurol</source><year>2002</year><volume>52</volume><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">12210786</pub-id><pub-id pub-id-type="doi">10.1002/ana.10265</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Pisalyaput</surname><given-names>K</given-names></name><name><surname>Galvan</surname><given-names>M</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name></person-group><article-title>Macrophage colony stimulatory factor and interferon-gamma trigger distinct mechanisms for augmentation of beta-amyloid-induced microglia-mediated neurotoxicity</article-title><source>J Neurochem</source><year>2004</year><volume>91</volume><fpage>623</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">15485493</pub-id><pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02765.x</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Town</surname><given-names>T</given-names></name><name><surname>Paris</surname><given-names>D</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Suo</surname><given-names>Z</given-names></name><name><surname>Crawford</surname><given-names>F</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Mullan</surname><given-names>M</given-names></name></person-group><article-title>Microglial activation resulting from CD40-CD40L interaction after &#x003b2;-amyloid stimulation</article-title><source>Science</source><year>1999</year><volume>286</volume><fpage>2352</fpage><lpage>2355</lpage><pub-id pub-id-type="pmid">10600748</pub-id><pub-id pub-id-type="doi">10.1126/science.286.5448.2352</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Barger</surname><given-names>S</given-names></name><name><surname>Barnum</surname><given-names>S</given-names></name><name><surname>Bradt</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Cole</surname><given-names>GM</given-names></name><name><surname>Cooper</surname><given-names>NR</given-names></name><name><surname>Eikelenboom</surname><given-names>P</given-names></name><name><surname>Emmerling</surname><given-names>M</given-names></name><name><surname>Fiebich</surname><given-names>BL</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><name><surname>Frautschy</surname><given-names>S</given-names></name><name><surname>Griffin</surname><given-names>WS</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Hull</surname><given-names>M</given-names></name><name><surname>Landreth</surname><given-names>G</given-names></name><name><surname>Lue</surname><given-names>L</given-names></name><name><surname>Mrak</surname><given-names>R</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name><name><surname>O'Banion</surname><given-names>MK</given-names></name><name><surname>Pachter</surname><given-names>J</given-names></name><name><surname>Pasinetti</surname><given-names>G</given-names></name><name><surname>Plata-Salaman</surname><given-names>C</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Rydel</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Streit</surname><given-names>W</given-names></name><name><surname>Strohmeyer</surname><given-names>R</given-names></name><name><surname>Tooyoma</surname><given-names>I</given-names></name><name><surname>Van Muiswinkel</surname><given-names>FL</given-names></name><name><surname>Veerhuis</surname><given-names>R</given-names></name><name><surname>Walker</surname><given-names>D</given-names></name><name><surname>Webster</surname><given-names>S</given-names></name><name><surname>Wegrzyniak</surname><given-names>B</given-names></name><name><surname>Wenk</surname><given-names>G</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name></person-group><article-title>Inflammation and Alzheimer's disease</article-title><source>Neurobiol Aging</source><year>2000</year><volume>21</volume><fpage>383</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">10858586</pub-id><pub-id pub-id-type="doi">10.1016/S0197-4580(00)00124-X</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>GQ</given-names></name><name><surname>Rohde</surname><given-names>M</given-names></name><name><surname>McConlogue</surname><given-names>L</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><article-title>TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>612</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">11329064</pub-id><pub-id pub-id-type="doi">10.1038/87945</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>MI</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Botto</surname><given-names>M</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name></person-group><article-title>Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><fpage>6457</fpage><lpage>6465</lpage><pub-id pub-id-type="pmid">15269255</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0901-04.2004</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mott</surname><given-names>RT</given-names></name><name><surname>Ait-Ghezala</surname><given-names>G</given-names></name><name><surname>Town</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Vendrame</surname><given-names>M</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Ehrhart</surname><given-names>J</given-names></name><name><surname>Mullan</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name></person-group><article-title>Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production</article-title><source>Glia</source><year>2004</year><volume>46</volume><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">15095367</pub-id><pub-id pub-id-type="doi">10.1002/glia.20009</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGeer</surname><given-names>PL</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name></person-group><article-title>Inflammation and neurodegeneration in Parkinson's disease</article-title><source>Parkinsonism Relat Disord</source><year>2004</year><volume>10</volume><fpage>S3</fpage><lpage>S7</lpage><pub-id pub-id-type="pmid">15109580</pub-id><pub-id pub-id-type="doi">10.1016/j.parkreldis.2004.01.005</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singhrao</surname><given-names>SK</given-names></name><name><surname>Neal</surname><given-names>JW</given-names></name><name><surname>Morgan</surname><given-names>BP</given-names></name><name><surname>Gasque</surname><given-names>P</given-names></name></person-group><article-title>Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease</article-title><source>Exp Neurol</source><year>1999</year><volume>159</volume><fpage>362</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">10506508</pub-id><pub-id pub-id-type="doi">10.1006/exnr.1999.7170</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>LV</given-names></name><name><surname>Leitner</surname><given-names>WP</given-names></name><name><surname>Staples</surname><given-names>MK</given-names></name><name><surname>Anderson</surname><given-names>DH</given-names></name></person-group><article-title>Complement activation and inflammatory processes in Drusen formation and age related macular degeneration</article-title><source>Exp Eye Res</source><year>2001</year><volume>73</volume><fpage>887</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">11846519</pub-id><pub-id pub-id-type="doi">10.1006/exer.2001.1094</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>GG</given-names></name><name><surname>Gasque</surname><given-names>P</given-names></name><name><surname>Strobel</surname><given-names>T</given-names></name><name><surname>Lindeck-Pozza</surname><given-names>E</given-names></name><name><surname>Strohschneider</surname><given-names>M</given-names></name><name><surname>Ironside</surname><given-names>JW</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name><name><surname>Guentchev</surname><given-names>M</given-names></name></person-group><article-title>Complement activation in human prion disease</article-title><source>Neurobiol Dis</source><year>2004</year><volume>15</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">14751767</pub-id><pub-id pub-id-type="doi">10.1016/j.nbd.2003.09.010</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Burdick</surname><given-names>D</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><name><surname>Cotman</surname><given-names>CW</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name></person-group><article-title>&#x003b2;-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain</article-title><source>J Immunol</source><year>1994</year><volume>152</volume><fpage>5050</fpage><lpage>5059</lpage><pub-id pub-id-type="pmid">8176223</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>LJ</given-names></name><name><surname>Mealey</surname><given-names>R</given-names></name><name><surname>Marsh</surname><given-names>JrHC</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name><name><surname>Connolly</surname><given-names>ES</given-names><suffix>Jr</suffix></name><name><surname>Pinsky</surname><given-names>DJ</given-names></name></person-group><article-title>Neuronal protection in stroke by an sLe<sup>x</sup>-glycosylated complement inhibitory protein</article-title><source>Science</source><year>1999</year><volume>285</volume><fpage>595</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">10417391</pub-id><pub-id pub-id-type="doi">10.1126/science.285.5427.595</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terai</surname><given-names>K</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><article-title>Neurons express proteins of the classical complement pathway in Alzheimer disease</article-title><source>Brain Res</source><year>1997</year><volume>769</volume><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">9374211</pub-id><pub-id pub-id-type="doi">10.1016/S0006-8993(97)00849-4</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><article-title>Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain</article-title><source>Brain Res</source><year>1997</year><volume>769</volume><fpage>391</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">9374212</pub-id><pub-id pub-id-type="doi">10.1016/S0006-8993(97)00850-0</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rozovsky</surname><given-names>I</given-names></name><name><surname>Morgan</surname><given-names>TE</given-names></name><name><surname>Willoughby</surname><given-names>DA</given-names></name><name><surname>Dugich-Djordjevich</surname><given-names>MM</given-names></name><name><surname>Pasinetti</surname><given-names>GM</given-names></name><name><surname>Johnson</surname><given-names>SA</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name></person-group><article-title>Selective expression of Clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro</article-title><source>Neuroscience</source><year>1994</year><volume>62</volume><fpage>741</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">7870303</pub-id><pub-id pub-id-type="doi">10.1016/0306-4522(94)90473-1</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Botto</surname><given-names>M</given-names></name><name><surname>Dell'agnola</surname><given-names>C</given-names></name><name><surname>Bygrave</surname><given-names>AE</given-names></name><name><surname>Thompson</surname><given-names>EM</given-names></name><name><surname>Cook</surname><given-names>HT</given-names></name><name><surname>Petry</surname><given-names>F</given-names></name><name><surname>Loos</surname><given-names>M</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name><name><surname>Walport</surname><given-names>MJ</given-names></name></person-group><article-title>Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies</article-title><source>Nat Genet</source><year>1998</year><volume>19</volume><fpage>56</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">9590289</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mevorach</surname><given-names>D</given-names></name><name><surname>Mascarenhas</surname><given-names>JO</given-names></name><name><surname>Gershov</surname><given-names>D</given-names></name><name><surname>Elkon</surname><given-names>KB</given-names></name></person-group><article-title>Complement-dependent clearance of apoptotic cells by human macrophages</article-title><source>J Exp Med</source><year>1998</year><volume>188</volume><fpage>2313</fpage><lpage>2320</lpage><pub-id pub-id-type="pmid">9858517</pub-id><pub-id pub-id-type="doi">10.1084/jem.188.12.2313</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ogden</surname><given-names>CA</given-names></name><name><surname>deCathelineau</surname><given-names>A</given-names></name><name><surname>Hoffmann</surname><given-names>PR</given-names></name><name><surname>Bratton</surname><given-names>D</given-names></name><name><surname>Ghebrehiwet</surname><given-names>B</given-names></name><name><surname>Fadok</surname><given-names>VA</given-names></name><name><surname>Henson</surname><given-names>PM</given-names></name></person-group><article-title>C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells</article-title><source>J Exp Med</source><year>2001</year><volume>194</volume><fpage>781</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">11560994</pub-id><pub-id pub-id-type="doi">10.1084/jem.194.6.781</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colangelo</surname><given-names>V</given-names></name><name><surname>Schurr</surname><given-names>J</given-names></name><name><surname>Ball</surname><given-names>MJ</given-names></name><name><surname>Pelaez</surname><given-names>RP</given-names></name><name><surname>Bazan</surname><given-names>NG</given-names></name><name><surname>Lukiw</surname><given-names>WJ</given-names></name></person-group><article-title>Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling</article-title><source>J Neurosci Res</source><year>2002</year><volume>70</volume><fpage>462</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">12391607</pub-id><pub-id pub-id-type="doi">10.1002/jnr.10351</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Albrecht</surname><given-names>S</given-names></name><name><surname>Bourdeau</surname><given-names>M</given-names></name><name><surname>Petzke</surname><given-names>T</given-names></name><name><surname>Bergeron</surname><given-names>C</given-names></name><name><surname>LeBlanc</surname><given-names>AC</given-names></name></person-group><article-title>Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease</article-title><source>Am J Pathol</source><year>2004</year><volume>165</volume><fpage>523</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">15277226</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>DG</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Hong</surname><given-names>YM</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Mook-Jung</surname><given-names>I</given-names></name><name><surname>Koh</surname><given-names>JY</given-names></name><name><surname>Jung</surname><given-names>YK</given-names></name></person-group><article-title>Induction of pro-apoptotic calsenilin/DREAM/KChIP3 in Alzheimer's disease and cultured neurons after amyloid-beta exposure</article-title><source>J Neurochem</source><year>2004</year><volume>88</volume><fpage>604</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">14720210</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Michaelis</surname><given-names>EK</given-names></name></person-group><article-title>Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging</article-title><source>Prog Neurobiol</source><year>1998</year><volume>54</volume><fpage>369</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">9522394</pub-id><pub-id pub-id-type="doi">10.1016/S0301-0082(97)00055-5</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lesort</surname><given-names>M</given-names></name><name><surname>Terro</surname><given-names>F</given-names></name><name><surname>Esclaire</surname><given-names>F</given-names></name><name><surname>Hugon</surname><given-names>J</given-names></name></person-group><article-title>Neuronal APP accumulates in toxic membrane blebbings</article-title><source>J Neural Transm</source><year>1997</year><volume>104</volume><fpage>497</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">9295181</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kagan</surname><given-names>BL</given-names></name><name><surname>Hirakura</surname><given-names>Y</given-names></name><name><surname>Azimov</surname><given-names>R</given-names></name><name><surname>Azimova</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>MC</given-names></name></person-group><article-title>The channel hypothesis of Alzheimer's disease: current status</article-title><source>Peptides</source><year>2002</year><volume>23</volume><fpage>1311</fpage><lpage>1315</lpage><pub-id pub-id-type="pmid">12128087</pub-id><pub-id pub-id-type="doi">10.1016/S0196-9781(02)00067-0</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoppini</surname><given-names>L</given-names></name><name><surname>Buchs</surname><given-names>PA</given-names></name><name><surname>Muller</surname><given-names>D</given-names></name></person-group><article-title>A simple method for organotypic cultures of nervous tissue</article-title><source>J Neurosci Methods</source><year>1991</year><volume>37</volume><fpage>173</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">1715499</pub-id><pub-id pub-id-type="doi">10.1016/0165-0270(91)90128-M</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>R</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name></person-group><article-title>Complement C1q expression induced by Abeta in rat hippocampal organotypic slice cultures</article-title><source>Exp Neurol</source><year>2004</year><volume>185</volume><fpage>241</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">14736505</pub-id><pub-id pub-id-type="doi">10.1016/j.expneurol.2003.09.023</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tenner</surname><given-names>AJ</given-names></name><name><surname>Volkin</surname><given-names>DB</given-names></name></person-group><article-title>Complement subcomponent C1q secreted by cultured human monocytes has subunit structure identical with that of serum C1q</article-title><source>Biochem J</source><year>1986</year><volume>233</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">3485427</pub-id></citation></ref><ref id="B36"><citation citation-type="other"><article-title>NIH image</article-title><year>2004</year><ext-link ext-link-type="uri" xlink:href="http://rsb.info.nih.gov/nih-image/download.html"/></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>X</given-names></name><name><surname>Gall</surname><given-names>CM</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Lynch</surname><given-names>G</given-names></name></person-group><article-title>Uptake and pathogenic effects of amyloid beta peptide 1&#x02013;42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists</article-title><source>Neuroscience</source><year>2002</year><volume>112</volume><fpage>827</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">12088742</pub-id><pub-id pub-id-type="doi">10.1016/S0306-4522(02)00132-X</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giulian</surname><given-names>D</given-names></name><name><surname>Haverkamp</surname><given-names>LJ</given-names></name><name><surname>Yu</surname><given-names>JH</given-names></name><name><surname>Karshin</surname><given-names>M</given-names></name><name><surname>Tom</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Kazanskaia</surname><given-names>A</given-names></name><name><surname>Kirkpatrick</surname><given-names>J</given-names></name><name><surname>Roher</surname><given-names>AE</given-names></name></person-group><article-title>The HHQK domain of &#x003b2;-amyloid provides a structural basis for the immunopathology of Alzheimer's disease</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>29719</fpage><lpage>29726</lpage><pub-id pub-id-type="pmid">9792685</pub-id><pub-id pub-id-type="doi">10.1074/jbc.273.45.29719</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aloisi</surname><given-names>F</given-names></name></person-group><article-title>Immune function of microglia</article-title><source>Glia</source><year>2001</year><volume>36</volume><fpage>165</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">11596125</pub-id><pub-id pub-id-type="doi">10.1002/glia.1106</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meda</surname><given-names>L</given-names></name><name><surname>Baron</surname><given-names>P</given-names></name><name><surname>Scarlato</surname><given-names>G</given-names></name></person-group><article-title>Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins</article-title><source>Neurobiol Aging</source><year>2001</year><volume>22</volume><fpage>885</fpage><lpage>893</lpage><pub-id pub-id-type="pmid">11754995</pub-id><pub-id pub-id-type="doi">10.1016/S0197-4580(01)00307-4</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>SD</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>SF</given-names></name><name><surname>Roher</surname><given-names>A</given-names></name><name><surname>Tourtellotte</surname><given-names>WW</given-names></name><name><surname>Rajavashisth</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Godman</surname><given-names>GC</given-names></name><name><surname>Stern</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>AM</given-names></name></person-group><article-title>Amyloid-&#x003b2; peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>5296</fpage><lpage>5301</lpage><pub-id pub-id-type="pmid">9144231</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.10.5296</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>H</given-names></name><name><surname>Wekerle</surname><given-names>H</given-names></name></person-group><article-title>Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration</article-title><source>J Neuropathol Exp Neurol</source><year>1998</year><volume>57</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9600191</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Streit</surname><given-names>WJ</given-names></name></person-group><article-title>Microglia and Alzheimer's disease pathogenesis</article-title><source>J Neurosci Res</source><year>2004</year><volume>77</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15197750</pub-id><pub-id pub-id-type="doi">10.1002/jnr.20093</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>A</given-names></name><name><surname>Nakagawa</surname><given-names>E</given-names></name><name><surname>Hatori</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>HB</given-names></name><name><surname>McLarnon</surname><given-names>JG</given-names></name><name><surname>Lee</surname><given-names>MA</given-names></name><name><surname>Kim</surname><given-names>SU</given-names></name></person-group><article-title>Generation and characterization of immortalized human microglial cell lines: expression of cytokines and chemokines</article-title><source>Neurobiol Dis</source><year>2001</year><volume>8</volume><fpage>1057</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">11741401</pub-id><pub-id pub-id-type="doi">10.1006/nbdi.2001.0437</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YB</given-names></name><name><surname>Nagai</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>SU</given-names></name></person-group><article-title>Cytokines, chemokines, and cytokine receptors in human microglia</article-title><source>J Neurosci Res</source><year>2002</year><volume>69</volume><fpage>94</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">12111820</pub-id><pub-id pub-id-type="doi">10.1002/jnr.10253</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lue</surname><given-names>LF</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name></person-group><article-title>Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures</article-title><source>Neurobiol Aging</source><year>2001</year><volume>22</volume><fpage>945</fpage><lpage>956</lpage><pub-id pub-id-type="pmid">11755003</pub-id><pub-id pub-id-type="doi">10.1016/S0197-4580(01)00311-6</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Kohsaka</surname><given-names>S</given-names></name></person-group><article-title>Intracellular signaling in M-CSF-induced microglia activation: role of Iba1</article-title><source>Glia</source><year>2002</year><volume>40</volume><fpage>164</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">12379904</pub-id><pub-id pub-id-type="doi">10.1002/glia.10149</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verdier</surname><given-names>Y</given-names></name><name><surname>Zarandi</surname><given-names>M</given-names></name><name><surname>Penke</surname><given-names>B</given-names></name></person-group><article-title>Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease</article-title><source>J Pept Sci</source><year>2004</year><volume>10</volume><fpage>229</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">15160835</pub-id><pub-id pub-id-type="doi">10.1002/psc.573</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combs</surname><given-names>CK</given-names></name><name><surname>johnson</surname><given-names>DE</given-names></name><name><surname>Cannady</surname><given-names>SB</given-names></name><name><surname>Lehman</surname><given-names>TM</given-names></name><name><surname>Landreth</surname><given-names>GE</given-names></name></person-group><article-title>Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of &#x003b2;-amyloid and prion proteins</article-title><source>J Neurosci</source><year>1999</year><volume>19</volume><fpage>928</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">9920656</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>DR</given-names></name><name><surname>Brunden</surname><given-names>KR</given-names></name><name><surname>Landreth</surname><given-names>GE</given-names></name></person-group><article-title>Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia</article-title><source>J Neurosci</source><year>1997</year><volume>17</volume><fpage>2284</fpage><lpage>2294</lpage><pub-id pub-id-type="pmid">9065490</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KL</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name></person-group><article-title>alpha1 Integrin activation: a link between beta-amyloid deposition and neuronal death in aging hippocampal neurons</article-title><source>J Neurosci Res</source><year>2004</year><volume>75</volume><fpage>688</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">14991844</pub-id><pub-id pub-id-type="doi">10.1002/jnr.20018</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Afagh</surname><given-names>A</given-names></name><name><surname>Cummings</surname><given-names>BJ</given-names></name><name><surname>Cribbs</surname><given-names>DH</given-names></name><name><surname>Cotman</surname><given-names>CW</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name></person-group><article-title>Localization and cell association of C1q in Alzheimer's disease brain</article-title><source>Exp Neurol</source><year>1996</year><volume>138</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">8593893</pub-id><pub-id pub-id-type="doi">10.1006/exnr.1996.0043</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldsmith</surname><given-names>SK</given-names></name><name><surname>Wals</surname><given-names>P</given-names></name><name><surname>Rozovsky</surname><given-names>I</given-names></name><name><surname>Morgan</surname><given-names>TE</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name></person-group><article-title>Kainic acid and decorticating lesions stimulate the synthesis of C1q protein in adult rat brain</article-title><source>J Neurochem</source><year>1997</year><volume>68</volume><fpage>2046</fpage><lpage>2052</lpage><pub-id pub-id-type="pmid">9109531</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>B</given-names></name><name><surname>Schmoll</surname><given-names>H</given-names></name><name><surname>Riederer</surname><given-names>P</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Platt</surname><given-names>D</given-names></name><name><surname>Popa-Wagner</surname><given-names>A</given-names></name></person-group><article-title>Complement C1q and C3 mRNA expression in the frontal cortex of Alzheimer's patients</article-title><source>J Mol Med</source><year>1995</year><volume>73</volume><fpage>465</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">8528750</pub-id><pub-id pub-id-type="doi">10.1007/BF00202265</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Klopp</surname><given-names>RG</given-names></name><name><surname>Weindruch</surname><given-names>R</given-names></name><name><surname>Prolla</surname><given-names>TA</given-names></name></person-group><article-title>Gene expression profile of aging and its retardation by caloric restriction</article-title><source>Science</source><year>1999</year><volume>285</volume><fpage>1390</fpage><lpage>1393</lpage><pub-id pub-id-type="pmid">10464095</pub-id><pub-id pub-id-type="doi">10.1126/science.285.5432.1390</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>MI</given-names></name><name><surname>Kawas</surname><given-names>CH</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name></person-group><article-title>Neuronal localization of C1q in preclinical Alzheimer's disease</article-title><source>Neurobiol Dis</source><year>2004</year><volume>15</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">14751769</pub-id><pub-id pub-id-type="doi">10.1016/j.nbd.2003.09.004</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hosokawa</surname><given-names>M</given-names></name><name><surname>Klegeris</surname><given-names>A</given-names></name><name><surname>Maguire</surname><given-names>J</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><article-title>Expression of complement messenger RNAs and proteins by human oligodendroglial cells</article-title><source>Glia</source><year>2003</year><volume>42</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">12730962</pub-id><pub-id pub-id-type="doi">10.1002/glia.10234</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spielman</surname><given-names>L</given-names></name><name><surname>Winger</surname><given-names>D</given-names></name><name><surname>Ho</surname><given-names>L</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Shohami</surname><given-names>E</given-names></name><name><surname>Pasinetti</surname><given-names>M</given-names></name></person-group><article-title>Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2</article-title><source>Acta Neuropathol (Berl)</source><year>2002</year><volume>103</volume><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">11810182</pub-id><pub-id pub-id-type="doi">10.1007/s004010100447</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>SD</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Fonseca</surname><given-names>MI</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name></person-group><article-title>Structural and functional evidence for microglial expression of C1qR<sub>P</sub>, the C1q receptor that enhances phagocytosis</article-title><source>J Leukoc Biol</source><year>2000</year><volume>67</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">10648005</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>SD</given-names></name><name><surname>Galvan</surname><given-names>MD</given-names></name><name><surname>Ferran</surname><given-names>E</given-names></name><name><surname>Garzon-Rodriguez</surname><given-names>W</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name></person-group><article-title>Antibody-mediated phagocytosis of the amyloid &#x003b2;-peptide in microglia is differentially modulated by C1q</article-title><source>J Immunol</source><year>2001</year><volume>166</volume><fpage>7496</fpage><lpage>7503</lpage><pub-id pub-id-type="pmid">11390503</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tohgi</surname><given-names>H</given-names></name><name><surname>Utsugisawa</surname><given-names>K</given-names></name><name><surname>Nagane</surname><given-names>Y</given-names></name></person-group><article-title>Hypoxia-induced expression of C1q, a subcomponent of the complement system, in cultured rat PC12 cells</article-title><source>Neurosci Lett</source><year>2000</year><volume>291</volume><fpage>151</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">10984629</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3940(00)01399-9</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>A</given-names></name><name><surname>Miyaishi</surname><given-names>O</given-names></name><name><surname>Kiuchi</surname><given-names>K</given-names></name><name><surname>Isobe</surname><given-names>K</given-names></name></person-group><article-title>Macrophage colony-stimulating factor is expressed in neuron and microglia after focal brain injury</article-title><source>J Neurosci Res</source><year>2001</year><volume>65</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">11433427</pub-id><pub-id pub-id-type="doi">10.1002/jnr.1125</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>R</given-names></name><name><surname>Jonakait</surname><given-names>GM</given-names></name></person-group><article-title>Neurotrophins and the anti-inflammatory agents interleukin-4 (IL-4), IL-10, IL-11 and transforming growth factor-beta1 (TGF-beta1) down-regulate T cell costimulatory molecules B7 and CD40 on cultured rat microglia</article-title><source>J Neuroimmunol</source><year>1999</year><volume>95</volume><fpage>8</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">10229111</pub-id><pub-id pub-id-type="doi">10.1016/S0165-5728(98)00248-3</pub-id></citation></ref><ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linard</surname><given-names>C</given-names></name><name><surname>Marquette</surname><given-names>C</given-names></name><name><surname>Mathieu</surname><given-names>J</given-names></name><name><surname>Pennequin</surname><given-names>A</given-names></name><name><surname>Clarencon</surname><given-names>D</given-names></name><name><surname>Mathe</surname><given-names>D</given-names></name></person-group><article-title>Acute induction of inflammatory cytokine expression after gamma-irradiation in the rat: effect of an NF-kappaB inhibitor</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2004</year><volume>58</volume><fpage>427</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">14751512</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2003.09.039</pub-id></citation></ref></ref-list></back></article>



